Growing with passion and conviction
For CLL Society, 2021 was a year of growth. It was a year of strengthening our capacity for meeting the unmet needs of the chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) community.

In 2021, CLL Society expanded our staff team to include three new positions, allowing us to bolster our programs and support resources for the CLL/SLL community. We restructured our Medical Advisory Board and Patient Advisory Board and created our Expert Medical Council to enhance the network of expert CLL physicians and those living with the disease who help guide our work by making us more attuned to breaking medical developments and persistent unmet needs of patients with CLL. Our advocacy efforts became much stronger in 2021, particularly around COVID-19; which gives us the foundation for broader advocacy efforts moving forward. Early 2021 also marked the beginning of two big undertakings for the organization, a complete website redesign and the founding of a CLL-specific research program in search of a cure. We are pleased to say both initiatives successfully came to fruition in the first half of 2022.

In 2021, we continued to advance the position of CLL Society as the leading organization for CLL/SLL patients, caregivers, and healthcare providers to turn to for vital education, advocacy, support, and research.
Thinking about the future

2021 was another year of growth and greater impact for CLL Society as we continued our fight for health equity, access to all kinds of care, and innovation for patients and caregivers dealing with a diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

Our core services, including support groups that meet virtually, are larger and busier, traffic on the website continues to help a broader and more diverse group, our free second opinion program is saving lives, our monthly webinars are more popular and highly rated than ever, and our peer-reviewed surveys such as our paper presented at the American Society of Hematology (ASH) annual convention are informing healthcare providers about what is vital to their CLL/SLL patients.

But 2021 was also a year for significant new programming.

We built the groundwork for a successful launch in 2022 of our first round of funding for preclinical and translational research. Many see CLL/SLL as a largely solved problem. However, we are not so naive. Our experience informs us of glaring unmet needs, including:

- **Double exposed or refractory disease** where patients have few options when failed by a BTK inhibitor (ibrutinib, acalabrutinib, and zanubrutinib) and by a BCL-2 inhibitor (venetoclax).
- **Richter’s Syndrome** still carries a dismal prognosis.
- **Reconstituting the immune system.** Too many with CLL/SLL are dying from infections and secondary cancers.
- **Curative therapies** when today, essentially all treatments are palliative or life-extending.

2021 saw CLL Society working in concert with the FDA, CDC, and other divisions of the HHS, and in the news (CNN, ABC, JAMA, etc.) publicly advocating for more equitable access for underserved communities to receive their best care, including clinical trials, expert care, and especially management as related to our immunocompromised state. This has involved research, campaigns, and partnerships to reach communities of color and others who have unique challenges getting state-of-the-art care. Mainly through our efforts, collaborations, and earned trust, the CLL/SLL community has become the face of the immunocompromised during the COVID-19 pandemic.
Growing with purpose and determination

Last year our reorganized and expanded **Medical Advisory Board**, **Patient Advisory Board**, and **Expert Medical Council** took on much greater responsibility in guiding the four pillars of CLL Society efforts: education, support, research, and advocacy. We are so grateful for their contribution to realizing our vision.

We helped lead the development and roll-out of the international inaugural **World CLL Day**.

We founded, funded, and guided the **International COVID-19 Blood Cancer Coalition (ICBCC)**. We continue to execute in a timely manner the CLLS Society 5-year plan for success.

None of this would be possible without the generous support of our donors and supporters, which allowed us to move swiftly when and where the need was greatest. The new research and advocacy efforts alone have significantly impacted how care is delivered, but their full impact is yet to be realized. CLL Society remains laser-focused on the needs of our community and has started to fill the gaps left as other nonprofits have moved away from prioritizing CLL/SLL.

We thank you for investing in our work to help all those with CLL/SLL live their best possible lives. Thanks also to our partners in industry and all the volunteers, including healthcare providers, patients, and caregivers, that have continued to recognize and support our unique services.

2022 and the years beyond promises more opportunities and challenges. With your support, we are poised to meet and exceed expectations. Let’s cure this. And let’s ensure all have equal access to any and all breakthroughs. That’s our goal. Please join us.

Steve Bloom, President of CLL Society Board Of Directors

Brian Koffman, MDCM (retired), MSEd, Co-Founder, Executive VP, Chief Medical Officer, and Director

Carly Boos, MEd, MBA, Executive Director
We envision a world in which the entire CLL/SLL community can equitably access quality education, support, and care, to lead healthier and richer lives.

Mission Statement

CLL Society is an inclusive, patient-centric, physician-curated nonprofit organization that addresses the unmet needs of the chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) community through patient education, advocacy, support, and research.

Table of Contents

A Year in Review 8
Patient Story: Meet Christina 9
The CLL Society Website 11
CLL/SLL Patient and Caregiver Programs 12
  Patient and Caregiver Support Groups 12
  Educational Programs 14
  Expert Access™ 16
  Ask the Experts 18
COVID-19 Response 21
Committed to Diversity, Equity, and Inclusion 27
CLL Society Leadership 28
Industry Partners 30
2021 Financials 31
Donor Acknowledgements 34
$558,854 dollars donated by individuals for the mission of CLL Society

943,733 website views in 2021, accumulating to 3.7 million since our 2015 website launch

Our website saw 337,263 new visitors in 2021

120 individuals received a second opinion on their CLL diagnosis from a CLL expert physician through CLL Society’s Expert Access™ Program

99% of Expert Access™ participants would recommend the program to a fellow CLL patient

Over 500 questions from CLL/SLL patients and caregivers were answered through our Ask the Expert service

39 CLL Society Support Groups in the US and Canada convened monthly

Launched our first support group dedicated towards addressing the needs of a unique demographic, physicians with CLL, with plans to offer more in the future

604 new members joined a CLL Society Support Group, totaling 2,529 individuals receiving peer-to-peer support and navigating their diagnosis surrounded by a community of fellow patients and caregivers

Produced 11 Educational Programs reaching a combined total of 5,252 attendees
Patient Story: Meet Christina

“After my diagnosis of chronic lymphocytic leukemia (CLL), others offered me advice and solutions about nutrition, quick cures, exercises, mental health and books, lots of books. It filled my soul to see how many people cared enough to try and help me. Many did not realize that I had trained as a professional athlete when I was younger and have taken good care of my health and my heart, my nutrition was on-point but yet, I still was diagnosed with cancer which was confusing and felt unfair. My exercise regimens began to change based upon my strength and overall health “gauge” of the day but I did finally go cold turkey with quitting sugar and candy, becoming militant about rejecting any form of it. I had started yoga prior to CLL and I’m grateful that I could practice throughout this journey.

Something very important changed in me the day my clinical trial oncologist invited me to hear him speak at a CLL Society event in my home town. I had no clue at the time how my life would change for the better by turning pain and sometimes sadness into productivity by helping others in my exact position. I asked a CLL Society representative who attended why our state did not have a support group, and he boldly asked me and another individual, my now co-facilitator, to start one. Seeing that we lacked confidence in our ability to commit at the moment, he kept pressing and encouraging us. After all we are patients, we had good days and tough days, how could we support others? Now we are good friends that run our meetings with confidence, ease, and a great support of each other.

Our group started meeting in person prior to the pandemic and my energy surged before and during the meetings, my heart was full and I felt happy to see that some of the other members’ anxiety would subside or we would share some laughs in the face of adversity. Finally, I had found others who understood and felt like I do, and I could share my new experimental treatment information with them. The pandemic didn’t really slow us down, one of my best memories over Zoom was all of us giddy with the fact that others now had to wear masks like some of us were already doing prior, we fit in again! Many have become proactive bringing research and new information for all of us and we look forward to seeing those familiar faces in our now-growing group each and every month. It helps me as much as it helps our members and for that I am truly grateful.”

Christina Fisher, Portland CLL Society Support Group Co-facilitator
CLL Patient since 2013, Oregon
Growing the information that changes lives
The CLL Society website is the principal means through which we serve the CLL and SLL community by providing reliable, physician-curated information on the biology of CLL, treatment options, resources for care management, and support.

We empower patients, caregivers, and loved ones with knowledge so that they may become informed self-advocates capable of engaging in shared decision-making conversations with their healthcare team and making educated decisions for their care management.

With COVID-19 proving to be a rapidly evolving disease in 2021, available information on protection and treatment options for the disease was constantly evolving. It became of vital importance for us to provide updates on the latest data, research, public health guidelines and tools, as well as create patient-focused resources to ensure our vulnerable community was equipped with the information they needed to protect their health and safety.

**Website Redesign**

Since the launch of the CLL Society website in 2015, we have seen it receive 3.7 million views, reaching tens of thousands of CLL/SLL patients, caregivers, loved ones, healthcare providers, and others in need of a trustworthy source to provide them with information on the disease that has deeply impacted their lives. Our audience continues to grow every year, as an 11 percent increase in website traffic was seen in 2021 over the previous year.

We knew the growth of our audience meant we had to take our website’s small-scale beginnings to the next level. We had to re-envision the way in which we bring crucial information and support to our community in order to continue meeting their needs.

A complete redesign of our website began in 2021. Our goal was to create a more user-friendly experience for all who visit the website that would make our educational content and programs more accessible, and meet people where they are in their treatment journeys. With the new website, we intend for our reach to grow further and meet the many individuals impacted by CLL/SLL who are not yet accessing the services CLL Society has to offer them.

Setting our sights on a 2022 launch date, CLL Society was not only working to increase our capacity to reach our mission but to become the leading organization for all individuals impacted by CLL/SLL.

“"This is a small token of my appreciation of all your hard work at CLL Society. Being part of the Support Group Facilitators as well as a member has given me a feeling of belonging to a family and not being alone isolated in my fight. For this, I thank you and keep up the good work and the flow of related information. With warm regards.”

Bob Barton
CLL Patient since 2008
Massachusetts
CLL/SLL PATIENT AND CAREGIVER PROGRAMS

CLL Society Patient and Caregiver Support Groups

CLL Society Support Groups remained virtual in 2021 due to the risk COVID-19 continues to pose to our immunocompromised community. CLL Society knows the more knowledgeable patients are about their disease the better they can advocate for receiving their best care. In 2021, CLL Society Support Groups continued to teach patients the biology of CLL/SLL and various options for treatment in addition to facilitating meaningful peer-to-peer emotional support. By the end of 2021, our support group base had grown by 24% from 2020, providing support to 2,529 individuals.

This year, we began expanding our support group program.

We felt it was important to advance the support we provide to our community by connecting them to those with shared experiences. The Physicians with CLL Support Group launched as our first support group to be dedicated towards meeting the needs of a unique demographic rather than determined by geographic location. We look forward to offering more topic-focused support groups in the future.

“I never expected to find a support group as helpful as this one has turned out to be. I thought that the dialogue would be too much about emotional and psychological coping strategies. Instead, I have learned a lot from other attendees about specifics of treatment approaches, potential side effects, efficacy of available targeted therapies, altered vulnerability to COVID-19 and related effective protective measures, etc. Occasionally, a CLL expert is invited, and attendees can ask questions of him/her. The leadership of the group including the hosting has been excellent.”

Art Levit
Physician, CLL Patient since 2021
California
Growing an informed and connected community
Educational Programs

CLL Society educational programs are presented in collaboration with CLL expert healthcare providers, patients, and caregivers, offering a time to dive deeper into a diverse array of topics in CLL/SLL. We believe, as our motto states, Smart Patients Get Smart Care™.

Each program reaches an average of 412 individuals in need of vital education on how to manage their disease. Our 2021 educational programs built off the topics discussed in 2020 to offer our community with a compounding learning experience from year to year.

Educating people about CLL/SLL as a disease will always remain at the core of our work.

Although, to improve the lives of CLL/SLL patients and their loved ones holistically we feel we have a responsibility to address issues beyond scientific matters. That is why in 2021 we held the webinar Getting Maximum Benefit from Doctor Appointments which offered practical tips for how to keep track of information and be prepared to engage in conversations of shared decision-making with one’s healthcare team. Later in the year we hosted our Giving Care to the Caregiver webinar which focused on strategies for promoting emotional wellbeing for caregivers in recognition of the vital but taxing role they play in caring for someone with a chronic cancer.

2021 Webinars
- Getting the Maximum Benefit from Doctors Appointments
- Learning to Decode your Blood Test Results for CLL
- Revisiting PI3K Inhibitors for the Treatment of CLL: Are They Living Up to Their Promise?
- Giving Care to the Caregiver

2021 Education Forums
- ASH 2020 Comes to You!
- CAR-T Ed Forum: The Basic Science and Latest Data
- Testing Ed Forum: The Right Tests at the Right Time
- CLL Society and Huntsman Cancer Institute 5th Annual Patient & Caregiver Educational Forum

2021 COVID-19 Virtual Community Meetings
- Contagion, Variants, and Vaccines
- The Delta Variant and Staying Protected
- Are Monoclonal Antibodies What the CLL Community Has Been Waiting For?

“Thank you so much for providing these webinars. They mean the world to us. Because of you, we now feel connected and capable of coping. Before we were alone and lost.”

Karen Bauder
Caregiver since 2018
Hawaii
“Your forum was excellent through and through—the presenters, the content, the pacing, the visuals — all of it. I especially loved the talk by the patient with CLL — I found her story compelling and felt reassured and hopeful after hearing her. I am so impressed with the CLL Society and the remarkable depth and breadth it offers. When my husband was diagnosed we were afraid and incredibly overwhelmed. We are so grateful to have found you. The CLL Society provides us high-quality, ongoing education that makes all the difference in our daily lives. We are now proud monthly donors. Thank you for doing this invaluable work in the way that you do!”

Lucia Z, Caregiver since 2021, Texas
Expert Access™ Program

Receiving care for one’s CLL/SLL from an expert physician has been proven to lead to better health outcomes and increase overall survivorship. Unfortunately, expert care is not easy to come by with CLL being a rare disease. For those who lack access to a CLL expert physician, our Expert Access™ Program continues to facilitate connections between patients and expert physicians in CLL.

In 2021, 120 individuals benefited from a free, second-opinion consultation with a CLL expert physician where they received individualized advice on treatment options and care management for their unique form of CLL.

As a result of their consultation, 77% of participants stated they would make a change or take follow-up action regarding their current care management plan. We are proud to continue increasing access to quality care and, in the process, improve health equity by reducing common barriers to healthcare like geographic location and insurance coverage.

“Given how rapidly the field of CLL is evolving, I think it’s helpful for CLL patients to have access to individualized advice from a CLL specialist, and I feel privileged to have the opportunity to provide such advice to patients who may not otherwise have the ability to access this type of care.”

CLL Society Expert Access™ Program Physician

CLL SOCIETY IN THE NEWS

Are You Receiving the Best Possible Care for Your CLL?
Patricia Koffman, HealthWell Foundation, 9/15/2021
Co-Founder and Communications Director Patricia Koffman authored an article featured by HealthWell Foundation sharing the positive impact of CLL Society’s Expert Access™ Program.
“Thank you so much for the consultation with an expert CLL specialist. The process was easy, supportive, and led to a consultation that changed the way I think about my CLL status and also how to think about risk to COVID-19. I have new information on how to assess progression to treatment, what test results to pay attention to, the importance of seeking a CLL specialist when it is time to treat, and more confidence that active surveillance is the right approach. I also feel happy as the outcome was encouraging, but even if the outcome or prognosis had been less positive having a world-class CLL expert share an opinion with me is far superior to “guessing” based on independent research. Thank you CLL Society — I am so grateful for this service especially during the COVID-19 pandemic when travel would increase health risk.”

Stacey Holland, CLL patient since 2018, Iowa
Ask the Experts Program

CLL is complex, and we understand that people have questions no matter how many years they have been living with the chronic disease, what line of treatment they are on, or if they are still in Watch and Wait. CLL Society’s Ask the Experts service offers people a place to get personalized answers to their pressing questions about CLL/SLL biology, treatment options, COVID-19, or any other disease-related topic from our experts.

Due to developments in the COVID-19 pandemic, we saw a substantial increase in the sheer volume of questions received and answered through this program compared to previous years, with over 500 questions asked in 2021.

CLL Society Experts
- Ask the Doctor
- Ask the Laboratory Scientist
- Ask the RN (Registered Nurse)
- Ask the Palliative Care/Hospice Doctor
- Ask the Pharmacist

“The vision and mission of the CLL Society are aligned with the needs of the patient and medical community. I recently participated in a CLL support group and am just beginning to mine the information at the website. It is an impressive organization that provides much needed and helpful information. Well worth supporting.”

Jim Coons
CLL Patient since 2017
New Mexico
Growing as a catalyst for change
As research on COVID-19 grew in 2021 and a greater understanding of the novel virus was formed by the scientific community, we came to learn how the SARS-CoV-2 virus specifically impacts those who are immunocompromised and thus more vulnerable to complications with infectious diseases.

In particular, when the SARS-CoV-2 mRNA and viral vector vaccines became widely distributed in 2021, we learned that those with immunodeficiencies, which includes patients with CLL/SLL regardless of treatment status, do not mount an adequate response for protection against contracting COVID-19. In response, CLL Society grew our advocacy efforts to push for patients with CLL/SLL to be afforded the resources they need to be protected in the same sense as those who are immunocompetent and offered protection through vaccination.

The year was also filled with exciting breakthroughs in COVID-19 drug development. One of the most notable breakthroughs for the immunocompromised community came from monoclonal antibody therapies that were developed for both pre-exposure protection against SARS-CoV-2 infection and treatment for COVID-19. CLL Society worked hard to make sure priority access to these life-saving therapies was given to those with CLL/SLL and other immunodeficiencies.

“As a CLL patient in the watch and wait period I slowly educated myself about the disease and treatment alternatives in the expectation that I would have to concur in some treatment decisions within the next 12 to 18 months. I accidentally discovered the CLL Society and am increasingly impressed by and utilizing the resources that it is making available to educate myself about the various facets of my disease and the different treatment options available. Although I now have started treatment with acalabrutinib, my pursuit of information on new treatments and trial results has continued and so I look forward to making continued use of the resources that the CLL Society offers.”

Ted Kleinman
CLL Patient since 2019
Washington, DC
Supporting the CLL/SLL Community Through COVID-19

CLL Society’s COVID-19 Virtual Community Meetings continued in 2021 as a series dedicated to providing updates on what we knew about COVID-19 at that point in time.

At our three virtual community meetings this year expert CLL physicians and infectious disease specialists joined us to discussed contagion, variants, and vaccines; the emergence of the Delta variant; and the promise monoclonal antibodies could bring for those who are immunocompromised. We found that these meetings addressed a new unmet need of the CLL/SLL community that arose with the COVID-19 pandemic, providing reassurance and answers in a time of great uncertainty.

In July of 2021, we released the first edition of our COVID-19 Action Plan.

Information and recommendations around COVID-19 protection were rapidly evolving, and we knew there was a need for our vulnerable immunocompromised community to have a reliable source of information on how they can prepare in advance for potential exposure, known exposure, and testing positive for COVID-19. Since it was first published in the summer, CLL Society has routinely updated the Action Plan as new information and treatments have become available. By the conclusion of the year, the plan had been viewed 9,842 times.

- Directions for Completing the COVID-19 Planning Checklist
- COVID-19 Planning Checklist: Complete Prior To Exposure
- COVID-19 Known Exposure Checklist
- Household Isolation Plan

We know that not everyone in the healthcare profession or the world at large understands the unique effects the COVID-19 pandemic has had on the immunocompromised community. Our four authored Official Statements in 2021 serve as a resource for the CLL/SLL community to use in conversations with healthcare professionals, family, and friends to explain their increased vulnerability to COVID-19 and the accommodations they need to stay protected.
Our COVID-19 Advocacy Efforts

By mid-February 2021, 46 states across the United States had made the announcement that cancer patients and others with immunodeficiencies were, or would be soon, prioritized to receive COVID-19 vaccination. We believe that our advocacy efforts on this matter played a role in it becoming reality.

CLICK, FILL, SEND VACCINE PRIORITIZATION CAMPAIGN TO STATE HEALTH DEPARTMENT OFFICIALS
Our community stepped up in our first-ever grassroots letter writing campaign to send over 4,000 letters to state health department officials advocating at the state level, where COVID-19 vaccine distribution decisions were made, for those who are immuno-compromised to be prioritized in receiving vaccination against SARS-CoV-2.

LETTER TO THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
CLL Society joined forces with fellow blood cancer patient advocacy organizations to submit a letter of official written comment to the ACIP committee of the CDC, a committee that makes decisions surrounding vaccination guidelines. The letter urged the committee to ensure blood cancer patients are prioritized to get vaccination against COVID-19 in their guidelines for states on SARS-CoV-2 vaccine distribution.

PRESIDENT BIDEN’S COVID-19 TASK FORCE
CLL Society was a part of creating a joint organizational letter that was submitted to the members of President Biden’s COVID-19 Task Force. The letter reminded members to follow the emerging data surrounding the increased risks in blood cancer patients, and urged the Task Force to advise states on streamlining vaccine registration processes to keep those processes from being overly burdensome for patients.

LETTERS TO THE GOVERNOR OF EVERY STATE
Seeing discrepancies in when COVID-19 vaccines would be available to cancer patients across the United States, CLL Society along with our partner organizations all worked to individually submit letters to governors of all 50 states communicating the importance of providing those with blood cancer priority access to COVID-19 vaccination.
Our COVID-19 Advocacy efforts — Continued

**MONOCLONAL ANTIBODIES SUPPORT**

Towards the end of 2021, monoclonal antibodies (mAb) were in development for COVID-19 treatment and pre-exposure prophylaxis. Knowing the benefit mAb treatments would provide to those with CLL/SLL, CLL Society was hard at work, constantly in conversation with top government officials to ensure that the certain individuals who were afforded access to pre-exposure monoclonal antibody therapies were specifically those who are immunocompromised.

**FORMING AN INTERNATIONAL COVID-19 BLOOD CANCER TASKFORCE**

Seeing how our community was continually left behind when it came to having their unique needs for protection against COVID-19 met, we knew we had to gather fellow blood cancer patient advocate organizations from around the world to work towards lasting change for this and future pandemics. In 2021 we began the foundational work for what became the International COVID-19 Blood Cancer Coalition (ICBCC) at the beginning of 2022. The ICBCC is a multi-stakeholder coalition consisting of representatives from the global patient advocacy and clinical communities who are dedicated to addressing the specific impacts of the COVID-19 pandemic on immunocompromised blood cancer patients, and to recommend solutions and actions to mitigate those risks. CLL Society remains an active participant in the Coalition and has provided funding to ensure this group is able to continue its important work for the immunocompromised.

**CLL SOCIETY IN THE NEWS**

Throughout the year, CLL Society’s Executive Vice President and Chief Medical Officer, Dr. Brian Koffman, was featured in six news articles bringing awareness to the unique impacts the COVID-19 pandemic has on the immunocompromised community and advocating for their needs to be met when it comes to pre-and post-exposure protection and treatment of COVID-19. Outlets Dr. Koffman was featured in include CNN Health, Ottawa Citizen (Canadian Newspaper), Journal of the American Medical Association, Washington Post, ABC10 News San Diego, and Health Professional Radio.
“This group has been a godsend. I was very worried when I was first diagnosed and was doing the math to figure out how many years before my 2 young kids reach adulthood. I googled CLL and came across the CLL Society and was happy to find the Twin Cities group. I find the meetings extremely helpful, not only in learning more about living with this disease, but perhaps more importantly making connections with people who are going through some of the same physical and mental challenges. It is great to be able to discuss these things with people who get it. The facilitator also kindly arranged an ad hoc phone call with me after some concerning test results in the early days after my diagnosis. I look forward to these group meetings! Great facilitators. Great conversations. Great friends. Thank you for making these meetings happen.”

Joe Goodhart, CLL patient since 2020, Minnesota
Growing with openness and compassion
In 2021 we began to formalize efforts toward diversity, equity, and inclusion (DEI). CLL Society’s foundations of a commitment to DEI included:

- Partnering with graduate students from Indiana University’s Master of Public Affairs Program who conducted a diversity audit of our organization and provided expansive recommendations for strengthening our commitment to diversity, equity, and inclusion in all facets of the organization.

- Conducting our first-ever DEI training for staff members with an outside organization.

- Restructuring our Patient Advisory Board with a focus on cultivating a group representative of the entire CLL/SLL community, considering factors such as age, race, ethnicity, gender, geographic location, and their role with CLL.

- Re-envisioning our mission and vision statements to emphasize inclusion of all those impacted by CLL/SLL.

- Supporting Mayo Clinic’s clinical trial looking at the genetics of CLL in African Americans and other minorities.

- Publishing reviews of abstracts on topics of DEI from large hematology/oncology conferences of the American Society of Hematology Annual Meeting (ASH), American Society of Clinical Oncology Annual Meeting (ASCO), and the European Hematology Association Congress (EHA).

While we still have a long way to go, we look forward to growing together in pursuit of better serving our diverse CLL/SLL community.
**CLL SOCIETY LEADERSHIP**

**Board of Directors**
Steven Bloom  
President and Chair
Sandy Bihlmeyer, MEd  
Secretary
William L. Cunningham-Corso*  
Treasurer
Robert Levis
Brian Koffman, MDCM (retired), MSEd  
Member at Large
John Pagel, MD, PhD*
Keith J. Watson, PhD
Susan O’Brien, MD**

**CLL Society Staff**
Brian Koffman, MD  
Chief Medical Officer
Carly Boos, MEd, MBA  
Executive Director
Patricia Koffman***  
Communications Director
Co-Founder
Liza Avruch, MPA  
Program Director
Robyn Brumble, MSN, RN  
Director of Scientific Affairs and Research
Brad Hedrick, MSCIS  
Information Technology Director
Nancy Day  
Program Coordinator
Ryan Whitman, MBA***  
Strategic Partnerships Specialist
Fernando Parra Chong**  
Strategic Partnerships Specialist
Albie Suozzi  
Executive Assistant
Nicole Kamphuis, MPA  
Communications Specialist

**Medical Advisory Board**
Anthony Mato, MD, MSCE, Chair  
Director, CLL Program
Memorial Sloan Kettering
Cancer Center
New York, NY
Alexey V. Danilov MD, PhD, Co-Chair  
Professor, Department of Hematology
Associate Director, Lymphoma Center
City of Hope National Medical Center
Duarte, CA
Matthew S. Davids, MD, MMSc  
Associate Director, Center for
Chronic Lymphocytic Leukemia
Dana Farber Cancer Institute
Boston, MA
Brian Hill, MD, PhD  
Taussig Cancer Center
Cleveland Clinic
Cleveland, OH
Nicole Lamanna, MD  
Department of Medicine, Columbia
University Medical College
Division of Hematology Oncology
Associate Professor of Clinical Medicine
New York, NY
Susan J. Leclair, Ph.D., CLS (NCA)  
Chancellor Professor Emerita
University of Massachusetts
Dartmouth, Massachusetts
Senior Scientist, Forensic DNA Associates, LLC
Dartmouth, MA
Sameer Parikh, MBBS, MD  
Assistant Professor, Hematology
Mayo Clinic
Rochester, MN
Alan Skarbnik, MD  
Director of the Lymphoproliferative
Disorders Program and Experimental
Therapeutics
Malignant Hematology
Novant Health
Charlotte, NC
Deborah Stephens, DO  
Assistant Professor of Hematology and
Hematologic Malignancies
The University of Utah Health/The Huntsman
Cancer Institute
Salt Lake City, UT

**Expert Medical Council**
Syed Ali Abutalib, MD  
Cancer Treatment Centers of America,
Affiliate of City of Hope
Zion, IL
Forrukh T. Awan, MD  
University of Texas Southwestern
Medical Center
Dallas, TX
Jacqueline C. Barrientos, MD, MS**  
Mount Sinai Medical Center
Comprehensive Cancer Center
Miami Beach, FL
Danielle M. Brander, MD  
Duke Cancer Institute
Durham, NC
Jennifer R. Brown, MD, PhD**  
Dana Farber Cancer Institute
Boston, MA
John M. Burke, MD**  
Rocky Mountain Cancer Centers
Aurora, CO
John C. Byrd, MD  
University of Cincinnati College of Medicine
Cincinnati, OH
Bruce D. Cheson, MD, FACP, FAAAS, FASCO**  
The Center for Cancer and Blood Disorders
Bethesda, MD
Catherine C. Coombs, MD**  
University of California, Irvine
Irvine, CA
Wei Ding, MD, PhD**  
Mayo Clinic
Rochester, MN
Ian Flinn, MD, PhD  
Sarah Cannon Center for Blood Cancer
Nashville, TN
Richard R. Furman, MD  
Weill Cornell Medical College
New York, NY
Thomas Henry III, RPh, CPh****
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Carmen N. Janes, PharmD, BCOP**
The Johns Hopkins Hospital
Baltimore, MD
Neil Kay, MD  
Mayo Clinic
Rochester, MN
Thomas Kipps, MD, PhD  
University of California, San Diego Moores Cancer Center  
La Jolla, CA

Adam Kittai, MD  
The Ohio State University  
Columbus, OH

Jean Louise Koff, MD, MSc**  
Winship Cancer Institute of Emory University  
Atlanta, GA

Lori Leslie, MD**  
John Theurer Cancer Center  
Hackensack, NJ

S. Shahzad Mustafa, MD  
University of Rochester School of Medicine and Dentistry  
Rochester, NY

John M. Pagel, MD, PhD*  
Formerly at Swedish Cancer Institute  
Seattle, WA

Krish Patel, MD  
Swedish Cancer Institute  
Seattle, WA

Tycel J. Phillips, MD**  
University of Michigan  
Ann Arbor, MI

Lindsey Roeker, MD  
Memorial Sloan Kettering Cancer Center  
New York, NY

Steven T. Rosen, MD, FACP  
City of Hope Comprehensive Cancer Center  
Duarte, CA

Mazyar Shadman, MD, MPH  
Fred Hutchinson Cancer Research Center  
Seattle, WA

Sanjay Sharma, MD  
St. Jude Medical Center  
Fullerton, CA

Tanya Siddiqi, MD  
City of Hope Comprehensive Cancer Center  
Duarte, CA

William G. Wierda, MD, PhD  
The University of Texas MD Anderson Cancer Center  
Houston, TX

Adrian Wiestner, MD, PhD  
National Institutes of Health (NIH)  
Bethesda, MD

Heather Wolfe, MD**  
University of Texas Southwestern Medical Center  
Dallas, TX

Jennifer Woyach, MD**  
Ohio State University Comprehensive Cancer Center  
Columbus, OH

Laura J. Zitella, MS, RN, ACNP-BC, AOCN**  
University of California San Francisco  
San Francisco, CA

**International Patient Advocates**

Michael Rynne  
Caregiver  
Ireland

Deborah Sims  
Patient  
Australia

Nick York  
Patient  
United Kingdom

**Patient Advisory Board**

Bruce Wright, Chair  
Patient

Elizabeth Dechen**  
Patient

Terry Evans  
Patient

Stephen Feldman  
Patient

Jolianne Jones  
Patient

James Josie***  
Caregiver

Barbara Massey  
Patient

Howard Massey  
Caregiver

Raye Murphy  
Patient

Dan Patterson  
Patient

Wilbur (Rich) Richburg  
Patient

Christina Rodriguez Fuller  
Patient

Haleh Simi  
Patient

Albie Suozzi**  
Patient

Michael Turner  
Patient

Wayne Wells*  
Patient

Doreen Zetterlund**  
Patient

**International Partners**  
Formed 2022

Versha Banerji, MD, FRCP  
CancerCare Manitoba  
Winnipeg, Manitoba, Canada

Alina Gerrie, MD, MPh, FRCP  
University of British Columbia  
Vancouver, BC, Canada

Peter Hillmen, MD, PhD  
University of Leeds Teaching Hospitals NHS  
Leeds, United Kingdom

Talha Munir, MBBS, MRCP, FRCPath, PhD  
St James’s Hospital  
Leeds, United Kingdom

Guilherme Perini, MD  
Hospital Municipal da Vila Santa Catarina  
Sao Paulo, Brazil

Anna Schuh, MD, PhD, MRCP, FRCPath  
University of Oxford  
Oxford, United Kingdom

John Seymour, MBBS, FRACP, PhD  
Peter MacCallum Cancer Centre  
Melbourne, Australia

Kostas Stamatopoulos, MD, PhD  
CERTH, Centre for Research and Technology  
Hellas, Thessaloniki, Greece

Tamar Tadmor, MD  
Bnai Zion Medical Center  
Haifa, Israel

Constantine (Con) Tam, MBBS, MD, FRACP, FRCPA  
Alfred Hospital Melbourne  
Victoria, Australia
2021 Industry Advisory Council

CLL Society has a long and successful history of working with our industry partners to promote improved understanding of the CLL/SLL patient experience, to navigate the landscape of CLL, and provide essential education, services, and support to patients throughout their journey.

To further this collaboration, CLL Society launched our first Industry Advisory Council (IAC) in 2021. The IAC is comprised of companies committed to advancing initiatives for the CLL/SLL community. Members of the IAC support the mission and strategic objectives of CLL Society by providing input and insights from an industry perspective. Likewise, IAC members benefit from their affiliation with CLL Society by gaining insights from Society leaders, engaging with medical advisors, and accessing CLL Society’s vast network of providers, patients, and caregivers.

We are grateful to the following 2021 IAC Members:

Platinum Members
- AbbVie
- Adaptive
- AstraZeneca
- Janssen
- Pharmacyclics

Gold Members
- TG Therapeutics
- LOXO@Lilly

Silver Members

CLL Society received additional financial support from the following companies:
- AbbVie
- Adaptive
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
- Genentech
- Janssen
- Johnson & Johnson
- Loxo Oncology
- Merck
- Novartis
- Pharmacyclics
- Regeneron
- TG Therapeutics
2021 FINANCIALS

CLL Society 2021 Revenue

- $1,253,523 (54%)
- $559,821 (24%)
- $558,854 (23%)
TOTAL: $2,372,198

CLL Society 2021 Expenses

- $1,335,481 (84%)
- $194,878 (12%)
- $53,398 (4%)
TOTAL: $1,583,757
Grow with us
CELEBRATING THOSE THAT GIVE

CLL Society Giving Tuesday

CLL Society is incredibly grateful for the countless individuals who donate to our mission every day and keep us running. In 2021 CLL Society conducted our first-ever campaign for Giving Tuesday. With a goal of raising $20,000, you blew us away with the total amount of $51,832.12 raised from 227 individuals for the mission of CLL Society!

Thank you to everyone who contributed and made the campaign such a success!

Flighthalo’s CLL Benefit Bike Ride for CLL Society

Ryan Mitchell was diagnosed with chronic lymphocytic leukemia (CLL) in February of 2021. In the midst of searching for answers on the internet he found CLL Society. “One reason that a cancer diagnosis is difficult is because there are so many unknowns. I took advantage of their [CLL Society’s] Expert Access Program, and it is something I would recommend for any patient who is not currently seeing a CLL Specialist. The CLL Society was such a great resource that I wanted to give something back so that others can get the same help as I did,” said Ryan. On August 15, 2021, Ryan participated in the Portland Century Bike Ride, cycling over 90 miles and raising funds for the mission of CLL Society. By the end of the ride, Ryan had raised $4,507.49 for fellow CLL/SLL patients.

Thank you, Ryan!

Ryan Mitchell
CLL Patient since 2021
Vancouver, WA
Thank you to our Donors

CLL Society is incredibly grateful for the dedication of individuals, foundations, and corporations who continue to support our work year after year. We would not be able to provide CLL and SLL patients, caregivers, and healthcare professionals with the support and education we do without you. Thank you.

Acknowledged below are the individuals who donated $500 or more in 2021.* Beyond the names listed below, we received numerous donations of less than $500, while others donated more but wished to remain anonymous.

We are extremely grateful for every donation, regardless of the amount.

| $10,000+ | Goldberg Family Foundation  
| Anonymous - 4 donors | Greenlife Foundation  
| The Kaczmarek Family Charitable Fund | Kevin Halpin  
| Dr. & Mrs. Brian Koffman (Patricia) | Robert Hander  
| John H. Whiteford and Kitty C. Whiteford | Jim Hardy  
| $5,000 - $9,999 | Cookie Harris  
| Anonymous - 2 donors | Orrin Heller  
| John and Kathleen Bethell | Frank Hochfeld  
| M. Y. Buckenmayer Charitable Fund | William Hughes  
| Cunningham-Corso Family | Michael Iocca  
| Dennis Vicars and Lisa Driver Family Fund | Howard and Hannah Jarson  
| Iorio Family Fund | Jason Family Foundation  
| Howard and Barbara Massey | John and Anne Jetmundsen  
| Paul and Marie Kenyan | David Kotok  
| David W. Martin | Eileen and Larry Letts  
| Carol Muchin | Bruce and Kathleen Levi  
| Douglas H. and Betty J. Post | Joseph L. Liegl  
| Jim Rauch | Todd and Jeanelle Lindsey  
| Andrew Lippmann | Salvatore Marranca  
| David W. Martin | Michael Rossoni  
| Carol Muchin | Salamone Family Charitable Fund  
| Douglas H. and Betty J. Post | Roger and Nancy Sayler Charitable Fund  
| Jim Rauch | Judith Selander  
| David I. Roberts | Haleh Simi  
| Michael Rossoni | The Douglas A. & Phyllis G. Smith Charitable Trust of The Columbus Foundation  
| $1,000 - $4,999 | The Douglas A. & Phyllis G. Smith Charitable Trust of The Columbus Foundation  
| Anonymous - 9 donors | }
We made every effort to accurately recognize the donations listed above. If a donation is missing or misrepresented, we are truly apologetic. Please contact Nicole Kamphuis, at nkamphuis@clisociety.org for a resolution.

An up-to-date 2021 donor recognition page can be found on our website.

Thank you

Daniel Springer
Harvey H. Stern
Michelle Stonis
Nancy Byers-Teague and Brad Teague
The Dueisterdick Family Fund of the Ayco Charitable Foundation
The Marino Family
Vitulli Family Foundation of Park City Community Foundation
Mallory Woods
Harvey Yavil
Robert and Wanda Zimmer Helping Hands Fund of the Orange County Community Foundation

Daniel Springer
Harvey H. Stern
Michelle Stonis
Nancy Byers-Teague and Brad Teague
The Dueisterdick Family Fund of the Ayco Charitable Foundation
The Marino Family
Vitulli Family Foundation of Park City Community Foundation
Mallory Woods
Harvey Yavil
Robert and Wanda Zimmer Helping Hands Fund of the Orange County Community Foundation

$500 - $999
Anonymous - 11 donors
Mitch and Cindy Austin
The R. A. Barton Family
Brad and Jeanette Bassi
Sam Beard
Paul and Bonnie Blackmer
Brian and Connie Bolvin
Sharon Bouten
Keller Brengle Charitable Fund
Dr. Leonard Brzozowski
Carolyn Burton
Ron Campbell
Keith Chapman
Gregory Groce and Rachel Chrobak
Tracy Coates
Matthew Davids, MD
Cindy & Steve Delesie
Lenora Dziuba
Peter V. Elting
Jane Feldblum
Lisa and Jerome Feldman
Robbie and Jose Franco
James Frank
Ghodsizadeh Family Fund
Jill and Jim Gollinger
Geoff Grubbs
Holly and Joe Hagler
Gregory Hamilton

Kirk Hansen
Harold B. and Alice Hoffman Donor Advised Fund of the Jewish Community Foundation of the Milwaukee Jewish Federation
John & Anne Jetmundsen
Mike and Mary Kennedy
Jonathan Khuner
Charles G. Kogge
The Konicki-Chenard Fund
John Korach
Plaskett Kordisch Charitable Gift Fund
Gary Lansman
Miriam Lawrence
Leslie Leavens
Robert Linderman and Ida Granowitz
Leslie and Kevin Lloyd
Raymond A. Loyd
LSLK Fund
Francesca Luzuriaga
The Mary A. Mettler Fund
Diane Mitchell
William Mitchell
Ronald Morgan
Elaine and Rod Morris
Christopher Nolan
Jacquelynn Ostrander
Brian Re
True Ryndes
Roman and Patty Saienni
Jeff Schumer
Sue Shindell
Stuart Arnold Sirkinn
Richard Small
David Snow
Thomas F. Talbot
Michael and Judy Thomas
Edwin Turner
Douglas and Kerry Vincent
Patricia Ann Wallace
Holly Watson-Evans
Williams and Gardner Charitable Fund
Rachel Wolfe
Doug and Lynette Zezoff Donor Advised Fund

* We made every effort to accurately recognize the donations listed above. If a donation is missing or misrepresented, we are truly apologetic. Please contact Nicole Kamphuis, at nkamphuis@clisociety.org for a resolution. An up-to-date 2021 donor recognition page can be found on our website.
Learn how you can support the work of CLL Society by visiting www.cllsociety.org/donate-to-cll-society/